Abstract: Objective  To explore the effects of alogliptin combined with different insulin intensive regimens on the expression of microRNA-144(miR-144) and microRNA-142(miR-142) in patients with type 2 diabetes mellitus(T2DM). 
Methods  A total of 106 patients with T2DM treated in our hospital were selected as the research subjects, and they were divided into insulin pump group(n=53) and basic treatment group(n=53)according to the random number table method. Both groups were treated with alogliptin. In addition, the insulin pump group was treated with an insulin pump, and the basic treatment group was treated with subcutaneous insulin. A blood glucose meter was used to detect fasting blood glucose(FBG) and  2 h postprandial blood glucose(2 hBG) levels. Hb201+ fast hemoglobin detector was employed to detect hemoglobin(HbAlc) levels. Enzyme-linked immunosorbent assay was used for detection of C-reactive protein(CRP), tumor necrosis factor-α(TNF-α), and interleukin-6(IL-6) levels. Real-time fluorescent quantitative PCR method was applied to detect expression levels of miR-144 and miR-142. The total treatment cost, therapeutic effect and occurrence of adverse reactions between two groups were observed and compared. 
Results  After treatment, the levels of FBG, 2 hBG and HbAlc in the two groups were lower than those before treatment, and the levels of FBG, 2 hBG and HbAlc in the insulin pump group and the total treatment cost were lower than those in the basic treatment group(P＜0.05). After treatment, the levels of inflammatory factors in the two groups were lower than those before treatment, and the levels of inflammatory factors in the insulin pump group were lower than those in the basic treatment group(P＜0.05). After treatment, the expression of miR-144 in the two groups was lower than that before treatment, while the expression of miR-142 was higher than that before treatment. The expression of miR-144 in the insulin pump group was lower than that in the basic treatment group, while the expression of miR-142 was higher than that in the basic treatment group(P＜0.05). The total effective rate in the insulin pump group was higher than that in the basic treatment group(P＜0.05). There was no significant difference in the incidence of adverse reactions between two groups(P＞0.05). 
Conclusion  Alogliptin combined with insulin pump can effectively alleviate the clinical symptoms of patients with T2DM, reduce the expression of miR-144 and the incidence of complications, increase the expression of miR-142, shorten the treatment cycle, and reduce the treatment cost, showing a significant therapeutic effect.

Key words: diabetes mellitus, type 2, alogliptin, insulin